← Back to All US Stocks

Atai Beckley N.V. (ATAI) Stock Fundamental Analysis & AI Rating 2026

ATAI Nasdaq Pharmaceutical Preparations P7 CIK: 0001840904
Updated This Month • Analysis: Mar 20, 2026 • SEC Data: 2025-09-30
Combined AI Rating
SELL
90% Confidence
AGREEMENT
STRONG SELL
95% Conf
SELL
84% Conf

📊 ATAI Key Takeaways

Revenue: $3.0M
Net Margin: -3,811.9%
Free Cash Flow: $-56.0M
Current Ratio: 7.90x
Debt/Equity: 0.00x
EPS: $-0.59
AI Rating: STRONG SELL with 95% confidence
Atai Beckley N.V. (ATAI) receives a SELL rating with 90% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $3.0M, net profit margin of -3,811.9%, and return on equity (ROE) of -72.1%, Atai Beckley N.V. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete ATAI stock analysis for 2026.

Is Atai Beckley N.V. (ATAI) a Good Investment?

Claude

Atai Beckley N.V. exhibits severe financial distress with a pre-revenue or near-zero revenue business model generating massive operating losses of -74.1M on just 3.0M in revenue. The company is burning cash rapidly with -55.2M in operating cash flow and -56.0M in free cash flow, depleting its limited cash reserves despite maintaining a strong balance sheet from recent capital raises.

ChatGPT

Atai Beckley N.V.'s fundamentals remain weak: revenue is minimal and declining, while operating and net losses are exceptionally large relative to sales. The balance sheet is currently supported by high liquidity and no long-term debt, but negative free cash flow and a cash balance below one year of recent operating burn raise meaningful funding-risk concerns unless the company materially improves commercialization or secures new capital.

Why Buy Atai Beckley N.V. Stock? ATAI Key Strengths

Claude
  • + Strong liquidity position with 7.90x current ratio and 30.4M cash on hand
  • + Zero long-term debt providing financial flexibility
  • + Equity cushion of 159.8M limiting immediate solvency risk
ChatGPT
  • + Debt-free balance sheet with no long-term debt reducing financial leverage risk
  • + Strong near-term liquidity ratios indicate current obligations are well covered
  • + Positive equity base and sizable total assets provide some balance-sheet flexibility

ATAI Stock Risks: Atai Beckley N.V. Investment Risks

Claude
  • ! Massive operating losses of -74.1M with negative operating margin of -2450.5% indicating unsustainable business model
  • ! Severe cash burn rate of -56.0M annually will deplete cash reserves in approximately 6 months at current rate
  • ! Revenue of 3.0M is minimal and declining YoY, suggesting product commercialization failure or pre-revenue status
  • ! Net losses of -115.2M with negative ROE of -72.1% and ROA of -48.1% indicate fundamental value destruction
  • ! No clear path to profitability with operating expenses far exceeding revenue generation capacity
ChatGPT
  • ! Extreme negative operating and net margins show the business is far from self-sustaining
  • ! Operating cash burn is heavy relative to cash on hand, implying limited runway without improvement or external funding
  • ! Revenue base is very small and declined year over year, indicating weak growth quality and limited operating traction

Key Metrics to Watch

Claude
  • * Quarterly revenue growth trajectory and new product launches
  • * Operating cash burn rate and remaining cash runway
  • * Operating expense reduction progress and path to profitability
  • * Progress on clinical trials or regulatory approvals if pharmaceutical development company
  • * Working capital management and cash depletion timeline
ChatGPT
  • * Cash and equivalents relative to quarterly operating cash burn
  • * Revenue growth and operating loss trend

Atai Beckley N.V. (ATAI) Financial Metrics & Key Ratios

Revenue
$3.0M
Net Income
$-115.2M
EPS (Diluted)
$-0.59
Free Cash Flow
$-56.0M
Total Assets
$239.8M
Cash Position
$30.4M

💡 AI Analyst Insight

Strong liquidity with a 7.90x current ratio provides a solid financial cushion.

ATAI Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -2,450.5%
Net Margin -3,811.9%
ROE -72.1%
ROA -48.1%
FCF Margin -1,852.0%

ATAI vs Healthcare Sector: How Atai Beckley N.V. Compares

How Atai Beckley N.V. compares to Healthcare sector averages

Net Margin
ATAI -3,811.9%
vs
Sector Avg 12.0%
ATAI Sector
ROE
ATAI -72.1%
vs
Sector Avg 15.0%
ATAI Sector
Current Ratio
ATAI 7.9x
vs
Sector Avg 2.0x
ATAI Sector
Debt/Equity
ATAI 0.0x
vs
Sector Avg 0.6x
ATAI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Atai Beckley N.V. Stock Overvalued? ATAI Valuation Analysis 2026

Based on fundamental analysis, Atai Beckley N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-72.1%
Sector avg: 15%
Net Profit Margin
-3,811.9%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Atai Beckley N.V. Balance Sheet: ATAI Debt, Cash & Liquidity

Current Ratio
7.90x
Quick Ratio
7.90x
Debt/Equity
0.00x
Debt/Assets
33.3%
Interest Coverage
-53.37x
Long-term Debt
$0.0

ATAI Revenue & Earnings Growth: 5-Year Financial Trend

ATAI 5-year financial data: Year 2021: Revenue $20.4M, Net Income -$169.8M, EPS N/A. Year 2022: Revenue $20.4M, Net Income -$167.8M, EPS $-1.21. Year 2023: Revenue $314.0K, Net Income -$152.4M, EPS $-0.98. Year 2024: Revenue $314.0K, Net Income -$40.2M, EPS $-0.25.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Atai Beckley N.V.'s revenue has declined by 98% over the 5-year period, indicating business contraction. The most recent EPS of $-0.25 indicates the company is currently unprofitable.

ATAI Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-1,852.0%
Free cash flow / Revenue

ATAI Quarterly Earnings & Performance

Quarterly financial performance data for Atai Beckley N.V. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $40.0K -$26.3M $-0.16
Q2 2025 $273.0K -$27.7M $-0.14
Q1 2025 N/A -$26.4M $-0.15
Q3 2024 $40.0K -$21.9M $-0.14
Q2 2024 $172.0K -$33.0M $-0.21
Q1 2024 N/A -$26.7M $-0.17
Q3 2023 $24.0K -$21.9M $-0.14
Q2 2023 $170.0K -$33.0M $-0.21

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Atai Beckley N.V. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$55.2M
Cash generated from operations
Stock Buybacks
$500.0K
Shares repurchased (TTM)
Capital Expenditures
$791.0K
Investment in assets
Dividends
None
No dividend program

ATAI SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Atai Beckley N.V. (CIK: 0001840904)

📋 Recent SEC Filings

Date Form Document Action
Dec 5, 2025 8-K ny20060616x1_8k.htm View →
Nov 26, 2025 4 xslF345X05/form4.xml View →
Nov 12, 2025 10-Q atai-20250930.htm View →
Nov 12, 2025 8-K ef20058743_8k.htm View →
Nov 6, 2025 4 xslF345X05/form4.xml View →

Frequently Asked Questions about ATAI

What is the AI rating for ATAI?

Atai Beckley N.V. (ATAI) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are ATAI's key strengths?

Claude: Strong liquidity position with 7.90x current ratio and 30.4M cash on hand. Zero long-term debt providing financial flexibility. ChatGPT: Debt-free balance sheet with no long-term debt reducing financial leverage risk. Strong near-term liquidity ratios indicate current obligations are well covered.

What are the risks of investing in ATAI?

Claude: Massive operating losses of -74.1M with negative operating margin of -2450.5% indicating unsustainable business model. Severe cash burn rate of -56.0M annually will deplete cash reserves in approximately 6 months at current rate. ChatGPT: Extreme negative operating and net margins show the business is far from self-sustaining. Operating cash burn is heavy relative to cash on hand, implying limited runway without improvement or external funding.

What is ATAI's revenue and growth?

Atai Beckley N.V. reported revenue of $3.0M.

Does ATAI pay dividends?

Atai Beckley N.V. does not currently pay dividends.

Where can I find ATAI SEC filings?

Official SEC filings for Atai Beckley N.V. (CIK: 0001840904) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is ATAI's EPS?

Atai Beckley N.V. has a diluted EPS of $-0.59.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is ATAI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Atai Beckley N.V. has a SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is ATAI stock overvalued or undervalued?

Valuation metrics for ATAI: ROE of -72.1% (sector avg: 15%), net margin of -3,811.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy ATAI stock in 2026?

Our dual AI analysis gives Atai Beckley N.V. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is ATAI's free cash flow?

Atai Beckley N.V.'s operating cash flow is $-55.2M, with capital expenditures of $791.0K. FCF margin is -1,852.0%.

How does ATAI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -3,811.9% (avg: 12%), ROE -72.1% (avg: 15%), current ratio 7.90 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2025-09-30 | Powered by Claude AI